Intranasal delivery of interferon-β-loaded nanoparticles induces control of neuroinflammation in a preclinical model of multiple sclerosis: A promising simple, effective, non-invasive, and low-cost therapy

González, Luis; Acuña, Estefanía Flores; Arellano, Gabriel; Morales, Paola; Sotomayor, Paula; Oyarzún-Ampuero, Felipe; Naves, Rodrigo

doi:10.1016/j.jconrel.2020.11.019

Cited by 48 publications

(28 citation statements)

References 141 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The delivery of nanoencapsulated IFNs into the central nervous system (CNS) has significantly improved current systemic immunomodulator-based therapies for autoimmune diseases. Intranasal administration of the nanoformulation resulted in a significant reduction in the cytokine’s effective dose [ 154 ].…”

Section: Discussionmentioning

confidence: 99%

Section: Recent Encapsulation Forms Of Ifnsmentioning

confidence: 99%

See 1 more Smart Citation

Forms and Methods for Interferon’s Encapsulation

et al. 2021

View full text Add to dashboard Cite

Interferons (IFNs) are cytokines involved in the immune response that act on innate and adaptive immunity. These proteins are natural cell-signaling glycoproteins expressed in response to viral infections, tumors, and biological inducers and constitute the first line of defense of vertebrates against infectious agents. They have been marketed for more than 30 years with considerable impact on the global therapeutic protein market thanks to their diversity in terms of biological activities. They have been used as single agents or with combination treatment regimens, demonstrating promising clinical results, resulting in 22 different formulations approved by regulatory agencies. The 163 clinical trials with currently active IFNs reinforce their importance as therapeutics for human health. However, their application has presented difficulties due to the molecules’ size, sensitivity to degradation, and rapid elimination from the bloodstream. For some years now, work has been underway to obtain new drug delivery systems to provide adequate therapeutic concentrations for these cytokines, decrease their toxicity and prolong their half-life in the circulation. Although different research groups have presented various formulations that encapsulate IFNs, to date, there is no formulation approved for use in humans. The current review exhibits an updated summary of all encapsulation forms presented in the scientific literature for IFN-α, IFN-ß, and IFN-γ, from the year 1996 to the year 2021, considering parameters such as: encapsulating matrix, route of administration, target, advantages, and disadvantages of each formulation.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Recent Encapsulation Forms Of Ifnsmentioning

confidence: 99%

Forms and Methods for Interferon’s Encapsulation

et al. 2021

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

“…Although in vitro studies and in hepatocytes of Wistar rats administered with the formulation showed no evidence of toxicity, they observed mild side effects in the kidney, such as whiteness and pyelectasis[114]. Gonzalez et al (2021) studied the effect of intranasal administration of chitosan/cyclodextrin nanoparticles loaded with IFNß for the treatment of multiple sclerosis, finding that the nanoformulation was more effective than systemic administration of the cytokine in a murine model of C57BL/6 mice with better availability and immunomodulatory effects[115].IFNγ Segura et al in 2007 evaluated the macrophage activation capacity of IFNγ encapsulated in human serum albumin nanoparticles, observing an increase in the bactericidal effect against Brucella abortus of macrophages activated by the formulation in BALB/c mice [118]. Yin et al (2018) developed a nanoparticle…”

mentioning

confidence: 99%

Forms and Methods for Interferon's Encapsulation

Ramos¹,

Villacis²,

Vispo³

et al. 2021

Preprint

View full text Add to dashboard Cite

Interferons (IFNs) are cytokines involved in the immune response that act on innate and adaptive immunity. These proteins are natural cell-signaling glycoproteins expressed in response to viral infections, tumors, and biological inducers and constitute the first line of defense of vertebrates against infectious agents. They have been marketed for more than 30 years with considerable impact on the global therapeutic protein market thanks to their diversity in terms of biological activities. They have been used as single agents or with combination treatment regimens, demonstrating promising clinical results, resulting in 22 different formulations approved by regulatory agencies. The 163 clinical trials with currently active IFNs reinforce their importance as therapeutics for human health. However, their application has presented difficulties due to the molecules’ size, sensitivity to degradation, and rapid elimination from the bloodstream. For some years now, work has been underway to obtain new drug delivery systems to provide adequate therapeutic concentrations for these cytokines, decrease their toxicity and prolong their half-life in the circulation. Although different research groups have presented various formulations that encapsulate IFNs, to date, there is no formulation approved for use in humans. The current review exhibits an updated summary of all encapsulation forms presented in the scientific literature for these cytokines IFNα, IFNß, and IFNγ, from the year 1996 to the year 2021, considering parameters such as: encapsulating matrix, route of administration, and encapsulation.

show abstract

“…IFN-β can inhibit the release of glutamate and superoxide from activated microglia, protect neurons from neurotoxicity induced by microglia, and alleviate the neuroinflammatory response of MS ( Jin et al, 2007 ). Increasing the content of IFN-β in the CNS can downregulate the activation of microglia and suppress neuroinflammation in experimental autoimmune encephalitis (EAE) mice ( Gonzalez et al, 2021 ). Soluble IFN receptor (sIFNAR) enhances the immunomodulatory role of exogenous IFN-β in EAE by reducing the neuroinflammation induced by microglial activation ( Suardiaz et al, 2016 ).…”

Section: Modulators Influencing Microglial Phenotypic Transitionmentioning

confidence: 99%

Microglial Phenotypic Transition: Signaling Pathways and Influencing Modulators Involved in Regulation in Central Nervous System Diseases

Shui

Sun

et al. 2021

Front. Cell. Neurosci.

View full text Add to dashboard Cite

Microglia are macrophages that reside in the central nervous system (CNS) and belong to the innate immune system. Moreover, they are crucially involved in CNS development, maturation, and aging; further, they are closely associated with neurons. In normal conditions, microglia remain in a static state. Upon trauma or lesion occurrence, microglia can be activated and subsequently polarized into the pro-inflammatory or anti-inflammatory phenotype. The phenotypic transition is regulated by numerous modulators. This review focus on the literature regarding the modulators and signaling pathways involved in regulating the microglial phenotypic transition, which are rarely mentioned in other reviews. Hence, this review provides molecular insights into the microglial phenotypic transition, which could be a potential therapeutic target for neuroinflammation.

show abstract

Intranasal delivery of interferon-β-loaded nanoparticles induces control of neuroinflammation in a preclinical model of multiple sclerosis: A promising simple, effective, non-invasive, and low-cost therapy

Cited by 48 publications

References 141 publications

Forms and Methods for Interferon’s Encapsulation

Forms and Methods for Interferon’s Encapsulation

Forms and Methods for Interferon's Encapsulation

Microglial Phenotypic Transition: Signaling Pathways and Influencing Modulators Involved in Regulation in Central Nervous System Diseases

Contact Info

Product

Resources

About